BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition
Targeted cancer therapies are often associated with drug resistance, a phenomenon that has been observed with tyrosine kinase inhibitors (TKIs), widely used to treat leukaemia driven by BCR-ABL1 mutations. Markus Mueschen and colleagues describe a novel BCL6-dependent mechanism of drug resistance in...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) Editorial |
| Language: | English |
| Published: |
19 May 2011
|
| In: |
Nature
Year: 2011, Volume: 473, Issue: 7347, Pages: 384-388 |
| ISSN: | 1476-4687 |
| DOI: | 10.1038/nature09883 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/nature09883 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/nature09883 |
| Author Notes: | Cihangir Duy, Christian Hurtz, Seyedmehdi Shojaee, Leandro Cerchietti, Huimin Geng, Srividya Swaminathan, Lars Klemm, Soo-mi Kweon, Rahul Nahar, Melanie Braig, Eugene Park, Yong-mi Kim, Wolf-Karsten Hofmann, Sebastian Herzog, Hassan Jumaa, H. Phillip Koeffler, J. Jessica Yu, Nora Heisterkamp, Thomas G. Graeber, Hong Wu, B. Hilda Ye, Ari Melnick, Markus Müschen |
Search Result 1